Canadian Cancer Society – Data Saves Lives

“Data save lives. It’s as simple as that.” ? Thank you to the Canadian Cancer Society for having CanPath at the Cancer Data Community of Practice Workshop in Toronto this March. We were honoured to join this important conversation about improving Canada’s cancer data ecosystem because better data means better outcomes for all Canadians. Dr. Robin Urquhart, Atlantic PATH Scientific Director, says, “Data save lives. It’s as simple as that … How are we going to improve if we don’t know how we’re doing or if we don’t know where we have to improve, right? And data allows us to do that.” Dr. Donna Turner, Manitoba Tomorrow Project Scientific Director, says, “We really can’t manage what we don’t measure … We know that cancer data are actually relatively strong compared to other diseases, but we have so far to go.” A video from the Canadian Cancer Society of seven cancer stakeholders is available on LinkedIn.    

Government of Canada invests in breast cancer research at CanPath

Breast cancer is one of the most common cancers and the second leading cause of cancer-related death among women* in Canada, with one in eight women expected to be diagnosed in their lifetime. Early detection through screening can make treatment easier and improve survival rates. In April 2024, the US recommended starting breast cancer screening for women in their forties. However, Canada’s guidelines, updated in May 2024, did not fully adopt this change, highlighting the need for more research. To address these evidence gaps, the Honourable Mark Holland, Minister of Health for the Government of Canada, announced $295,000 in funding for CanPath to advance research for breast cancer screening. Minister Holland announced this funding at an in-person event at the Canadian Cancer Society, which also received funding for breast cancer public awareness. “When we think of breast cancer screening, data gaps, and the solutions research can deploy, it’s exceptionally important,” said the Honourable Mark Holland, Minister of Health, “so the partnership between the federal government and CanPath is very exciting.” CanPath will use existing Canadian cohort and administrative data to address three main objectives: Study differences in screening participation, treatments, and outcomes by race and ethnicity; Understand breast cancer risk factors and how they vary by race and ethnicity; and Analyze screening results, such as recall and biopsy rates, by race and ethnicity. This research aims to create better screening guidelines that consider the diverse needs of all Canadian women. “Anytime we can announce good news and talk about how we can advance research together is an exciting day. It’s so great to get to celebrate these wins together,” says Dr. Jennifer Brooks, Executive Director at CanPath. *Cisgendered women and other adults assigned female at birth, such as transgender men and nonbinary people. About CanPath The Canadian Partnership for Tomorrow’s Health (CanPath) is Canada’s largest population health cohort and a national platform for health research. Comprised of more than 330,000 volunteer participants across seven regional cohorts, including Atlantic PATH, CanPath is a unique platform that allows scientists to explore how genetics, environment, lifestyle, and behaviour interact and contribute to the development of chronic disease and cancer.  

Predicting chronic disease enabled by New Brunswick and Nova Scotia data linkage

  FOR IMMEDIATE RELEASE – Wednesday, June 5, 2024 Predicting chronic disease enabled by New Brunswick and Nova Scotia data linkage Predicting chronic disease has gotten faster and simpler with the linkage of data gathered from a longitudinal study involving over 34,000 participants and administrative health data routinely gathered by New Brunswick and Nova Scotia. A collaboration between the Atlantic Partnership for Tomorrow’s Health (Atlantic PATH) and New Brunswick Institute for Research, Data & Training (NB-IRDT), and Health Data Nova Scotia (HDNS) is an important opportunity for advancing health research. “I am absolutely thrilled to see these linkages happen,” said Dr. Robin Urquhart, Atlantic PATH Scientific Director. “Atlantic PATH is an incredibly rich resource to understand the health of Atlantic Canadians and all of the different factors, like our biology, behaviours, and environments, that impact our health. This new linkage activity makes our resource more powerful, giving us access to different sources of data to answer complex health questions affecting all Atlantic Canadians.” Atlantic PATH follows the health of participants from all four Atlantic Canadian provinces to help researchers discover why some people develop certain chronic diseases and cancers and others don’t in order to advance prevention and early diagnosis. Atlantic PATH is part of the Canadian Partnership for Tomorrow’s Health (CanPath), a pan-Canadian, longitudinal cohort studying Canadians’ health, behaviours and environments. “Not only is this historical, record-level data linkage activity, this work is crucial for Atlantic Canada, which has among the country’s highest rates of chronic disease and cancer,” said Dr. Ted McDonald, director of NB-IRDT. “Critically, it will enable researchers to focus on studies related to cancer and chronic disease that cannot be undertaken without linking the separate data sources. The data linkage has other important implications too, such as the potential to inform health policy and improve detection, prevention and treatment.” Based at the University of New Brunswick, NB-IRDT provides researchers with secure access to pseudonymized personal level administrative data and conducts research on policy topics to support evidence informed government decision-making. NB-IRDT is a member of Health Data Research Network Canada, a pan-Canadian network of data centres and research organizations. HDRN Canada facilitates access to multi-regional administrative data to address health challenges that cross boundaries and foster improvements in health and health equity. Within the Department of Community Health and Epidemiology at Dalhousie University, HDNS facilitates research and innovation in Nova Scotia by providing access to linkable administrative health data and analysis for research purposes in a remote, secure, controlled environment. HDNS is also a member of HDRN Canada. “This is an exciting opportunity for researchers across the Maritimes,” said Dr. Sam Stewart, director of HDNS. “Research cohorts like Atlantic PATH take a tremendous amount of work to collect, so it is paramount that we do everything we can to make that data as effective as possible. Linking Atlantic PATH data to the data resources at HDNS and NB-IRDT will enable researchers to discover key, long-term insights into the health of Canadians, and signal an important step forward in how research data can be leveraged and enhanced within the healthcare system.” “This is an exciting development, as this linkage includes data from participants in two provinces, so it is already multi-regional in nature,” said Dr. Kim McGrail, HDRN Canada Scientific Director. “It also builds on linkage of other regional CanPath cohorts across Canada, creating many new research opportunities that can help us to better understand chronic disease and how to prevent them.” New Brunswick and Nova Scotia are the first Atlantic Canadian provinces to link to Atlantic PATH, the result of a long and deliberate collaboration involving HDRN Canada, Atlantic PATH, CanPath, and administrative data holders in the four Atlantic provinces. Since the transfer of Atlantic PATH baseline data holdings to NB-IRDT and HDNS, researchers can now apply to link Atlantic PATH data to provincial administrative data holdings, such as screenings, hospitalizations, medication use, health outcomes and more. View the NB data holdings here View the NS data holdings here. MEDIA CONTACT: Dr. Kate Milberry Strategic Communications Manager HDRN Canada kate.milberry@hdrn.ca 604.306.1512

Webinar: Using CanPath to Support Innovative Health Research 

Using CanPath to Support Innovative Health Research  Join our colleagues, Dr. Parveen Bhatti (Scientific Director, BC Generations) and Sheraz Cheema (Data Manager, CanPath) on Wednesday, October 11th to learn about CanPath, types of questions the data can be used to address, and how the data can be accessed. Registration: https://t.co/m8PU92M881  

CITF COVID-19 Immunity Task Force Databank

CanPath and its regional cohorts, including Atlantic PATH, are proud to be part of the COVID-19 Immunity Task Force (CITF) Databank with our COVID-19 serology study that includes participants across the country. The CITF Databank data holdings include data from 21 studies, including six multi-province studies “representing a wide range of population and community data from various regions of Canada. Access is free and open to researchers everywhere.” Details: https://www.covid19immunitytaskforce.ca/citf-databank/

CanPath is Hiring: Research Operations Manager

Join the CanPath team as the new Research Operations Manager at the University of Toronto. Deadline: September 22, 2023. “CanPath is Canada’s largest population health cohort and a national platform for population-level health research. CanPath is studying the biology, behaviours and environments of Canadians to learn more about the causes of chronic disease and cancer for the good of our country and people around the world. As the CanPath Research Operations Manager, you will be integral to maximizing research funding, which includes conducting detailed analysis and applying and interpreting relevant policies. You will be responsible for directing the activities of a group of staff and therefore will be working together to drive CanPath’s objectives. Using your analytical, communication and problem-solving skills, you will support and collaborate with a diverse set of stakeholders and partners in applying and interpreting policies and procedures, policy issues, and drafting contracts and agreements.” Details: https://jobs.utoronto.ca/job/Toronto-CanPath-Research-Operations-Manager-ON/573838317/  

CSEB Conference Update

The CanPath team was well represented at the Canadian Society for Epidemiology & Biostatistics (CSEB) Conference in Halifax on June 26-28, 2023. We had representatives from the CanPath National Coordinating Centre, Atlantic PATH, CARTaGENE, the Manitoba Tomorrow Project, and the Ontario Health Study that showcased the groundbreaking research and resources available related to epidemiology and biostatistics within CanPath and the regional cohorts. Throughout the conference, CanPath and the regional cohorts were well-represented in various sessions and discussions, particularly regarding data linkage. Some notable presentations included: ? Dr. Robin Urquhart, Scientific Director of Atlantic PATH, co-presented a workshop on data repositories in Canada ? Dr. Ellen Sweeney, Research Director of Atlantic PATH, presented at a concurrent session about research at Atlantic PATH exploring environmental exposure to arsenic and cancer risk using toxicological and machine-learning methods ? Dr. Vikki Ho, co-Scientific Director of CARTaGENE, co-presented a workshop on mentorship for junior faculty and funding opportunities ? Nicholas Cheng, PhD candidate at the Ontario Institute for Cancer Research, presented at a concurrent session about his research on leveraging population health cohorts to identify cancer biomarkers in blood up to seven years before diagnosis ? Poster sessions featured CanPath, the Manitoba Tomorrow Project, the Ontario Health Study, CARTaGENE, and more, showcasing the exceptional research happening at the regional level and how they can support epidemiological and biostatistical projects. Please connect with us to learn more about these projects. We are proud to contribute to advancing this critical field and look forward to continuing our efforts to drive positive health outcomes for all.                                   #CSEBConference2023 #Epidemiology #Biostatistics #EveryoneCounts #HealthResearch #Cohort #PopulationHealth

New Toxicology Publication

Congratulations to Kalli Hood and team on their new publication in Frontiers in Public Health! Kalli’s Master’s research found an association between a history of cancer and arsenic speciation/metallome exposure in the Atlantic PATH cohort. This work is part of our larger focus on environment and cancer, and establishing toenails as an important biomarker representing ~18 months of exposure. Kalli is now working on her PhD focused on drinking water quality in the Department of Civil and Resource Engineering at Dalhousie University.  

Most CanPath study participants had infection-acquired antibodies but few suspected COVID-19

Dr. Victoria Kirsh presented at a CanPath webinar this week to present results from the SUPPORT-Canada study, funded by the federal COVID-19 Immunity Task Force (CITF). Data and blood spot samples were used from 22,300 participants from Atlantic PATH, CARTaGENE, the Ontario Health Study, Manitoba Tomorrow Project, Alberta’s Tomorrow Project, and BC Generations. Key findings include: 62% of participants had a COVID-19 infection based on anti-N measured antibody levels. Among those, 86% did not suspect they had ever had COVID-19. 95% of the COVID-19 infections were observed during the Omicron period. Risk of infection was increased among younger individuals, males, essential workers, and those who travelled. Participants with a reported COVID-19 infection reported symptoms from mild to severe, but few required hospitalization. The effectiveness of full or booster vaccination in preventing COVID-19 Omicron infection is short-term, only lasting 4 months. Time since last dose is a more important determinant of protection against infection than the number of doses. Antibody levels are correlates of vaccine-induced protection. Prior COVID-19 infection protects against reinfection for 8 months. The CanPath SUPPORT-Canada study has provided important findings related to the COVID-19 pandemic, vaccines and infections. With only 4 months of protection, these findings suggest that booster campaigns could be strategically used to rapidly boost immunity before upcoming waves of infection. Further, the longitudinal nature of CanPath participants ensures that we have a nationally representative population that can be followed for years to come (e.g., impact of Long COVID, future vaccinations, etc.). Link to recorded webinar: To come Link to webinar slide deck: https://www.covid19immunitytaskforce.ca/wp-content/uploads/2023/05/canpath-webinar-may-2023.pdf Link to CITF’s post: https://www.covid19immunitytaskforce.ca/most-canpath-study-participants-had-infection-acquired-antibodies-but-few-suspected-covid-19/